Bank of New York Mellon
VIVO

Bank of New York Mellon’s Meridian Bioscience Inc VIVO Stock Holding History

Bank of New York Mellon’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-409,347
Closed -$13.6M – 4496
2022
Q4 		$13.6M Sell
409,347
-28,995
-7% -$934K ﹤0.01% 1761
2022
Q3 		$13.8M Sell
438,342
-4,340
-1% -$141K ﹤0.01% 1706
2022
Q2 		$13.5M Sell
442,682
-6,672
-1% -$180K ﹤0.01% 1767
2022
Q1 		$11.7M Sell
449,354
-201
-0% -$4.78K ﹤0.01% 1980
2021
Q4 		$9.17M Sell
449,555
-14,133
-3% -$271K ﹤0.01% 2145
2021
Q3 		$8.92M Sell
463,688
-10,945
-2% -$218K ﹤0.01% 2192
2021
Q2 		$10.5M Sell
474,633
-26,273
-5% -$557K ﹤0.01% 2110
2021
Q1 		$13.1M Sell
500,906
-8,018
-2% -$191K ﹤0.01% 1943
2020
Q4 		$9.51M Sell
508,924
-6,759
-1% -$126K ﹤0.01% 2030
2020
Q3 		$8.76M Sell
515,683
-8,434
-2% -$164K ﹤0.01% 1924
2020
Q2 		$12.2M Sell
524,117
-13,513
-3% -$196K ﹤0.01% 1715
2020
Q1 		$4.51M Sell
537,630
-17,307
-3% -$146K ﹤0.01% 2121
2019
Q4 		$5.42M Buy
554,937
+38,288
+7% +$359K ﹤0.01% 2301
2019
Q3 		$4.9M Sell
516,649
-26,708
-5% -$281K ﹤0.01% 2298
2019
Q2 		$6.46M Sell
543,357
-158,915
-23% -$1.91M ﹤0.01% 2202
2019
Q1 		$12.4M Buy
702,272
+7,892
+1% +$131K ﹤0.01% 1850
2018
Q4 		$12.1M Sell
694,380
-127,082
-15% -$2.17M ﹤0.01% 1799
2018
Q3 		$12.2M Buy
821,462
+9,615
+1% +$149K ﹤0.01% 1908
2018
Q2 		$12.9M Buy
811,847
+13,937
+2% +$208K ﹤0.01% 1875
2018
Q1 		$11.3M Buy
797,910
+4,055
+0.5% +$60K ﹤0.01% 1911
2017
Q4 		$11.1M Sell
793,855
-77,705
-9% -$1.14M ﹤0.01% 1938
2017
Q3 		$12.5M Buy
871,560
+8,377
+1% +$120K ﹤0.01% 1877
2017
Q2 		$13.6M Buy
863,183
+9,713
+1% +$140K ﹤0.01% 1801
2017
Q1 		$11.8M Sell
853,470
-287,776
-25% -$4.02M ﹤0.01% 1875
2016
Q4 		$20.2M Buy
1,141,246
+26,125
+2% +$459K 0.01% 1518
2016
Q3 		$21.5M Sell
1,115,121
-276,647
-20% -$5.41M 0.01% 1421
2016
Q2 		$27.1M Sell
1,391,768
-42,273
-3% -$829K 0.01% 1208
2016
Q1 		$29.6M Buy
1,434,041
+27,524
+2% +$542K 0.01% 1168
2015
Q4 		$28.9M Sell
1,406,517
-126,690
-8% -$2.43M 0.01% 1152
2015
Q3 		$26.2M Buy
1,533,207
+52,582
+4% +$961K 0.01% 1232
2015
Q2 		$27.6M Buy
1,480,625
+35,747
+2% +$663K 0.01% 1256
2015
Q1 		$27.6M Buy
1,444,878
+800,186
+124% +$14.8M 0.01% 1266
2014
Q4 		$10.6M Sell
644,692
-1,486,479
-70% -$25.5M ﹤0.01% 1881
2014
Q3 		$37.7M Buy
2,131,171
+5,397
+0.3% +$106K 0.01% 1044
2014
Q2 		$43.9M Buy
2,125,774
+169,705
+9% +$3.49M 0.01% 986
2014
Q1 		$42.6M Sell
1,956,069
-45,795
-2% -$1.05M 0.01% 988
2013
Q4 		$53.1M Sell
2,001,864
-2,842
-0.1% -$69.9K 0.01% 855
2013
Q3 		$47.4M Sell
2,004,706
-63,531
-3% -$1.48M 0.01% 896
2013
Q2 		$44.5M Buy
+2,068,237
New +$44.6M 0.01% 893

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bank of New York Mellon's VIVO Position: Q1 2023 in Review

Bank of New York Mellon sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 409,347 shares — an estimated $13.6M sold.

Bank of New York Mellon first reported a position in VIVO in Q2 2013 and held it in 39 quarters. The position peaked at $53.1M in Q4 2013. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Bank of New York Mellon reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 409,347 Meridian Bioscience Inc shares in Q1 2023, an estimated $13.6M.
  • Bank of New York Mellon first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 39 quarters.
  • Bank of New York Mellon's Meridian Bioscience Inc position peaked at $53.1M in Q4 2013.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Bank of New York Mellon's 13F filing for Q1 2023, filed 9 May 2023.